Achaogen, headquartered in South San Francisco, announced that as part of its strategic update and corporate restructuring, it will eliminate 80 positions, or about 28 percent of staff.
Achaogen focuses on drugs to treat multi-drug resistant (MDR) gram-negative infections. On July 20, the company announced that Zemdri, which was approved in the U.S. for adults with complicated urinary tract infections (cUTI), was on the market. It was approved for cUTI, including pyelonephritis, due to specific Enterobacteriaceae. It was approved by the U.S. Food and Drug Administration (FDA) on June 25.
At the time, Blake Wise, the companys chief executive officer, stated, The challenge that healthcare providers face every day of address…
Read the full article at: https://www.biospace.com/article/achaogen-to-cut-80-jobs-as-part-of-corporate-restructuring/